Packaging
Körber absorbs Wilhelm Bähren to expand pharma packaging toolbox
Pharma packaging evolves with a key acquisition, poised to grow as the market doubles by 2028
Packaging
Pharma packaging evolves with a key acquisition, poised to grow as the market doubles by 2028
The Portuguese contract development and manufacturing organization (CDMO) Hovione continues its spray drying expansion with investments in its sites in Ireland and New Jersey, US.
The global CDMO has entered into several high-value manufacturing deals this year.
Genesis also announced a further investment from NVentures, NVIDIA’s venture capital arm.
Gifthealth Partners with United Digestive to boost patient access and procedure prep.
Private equity investors GHO Capital Partners and Ampersand Capital Partners have announced a merger agreement for the acquisition of Avid Bioservices.
The Boston-based startup Axonis Therapeutics has bagged $115 million in a Series A round to fuel its pipeline of treatments for pain, epilepsy and other conditions.
The US manufacturer NorthStar Medical Radioisotopes has unveiled a Contract Development & Manufacturing (CDMO) facility dedicated to the production and development of medical radioisotopes.
Merck’s acquisition of Modifi Biosciences will give it access to preclinical cancer drug candidates that target DNA repair processes.
The Boston-based biotech will use the new fundraise to develop its pipeline of drug candidates for conditions such as major depressive disorder and generalized anxiety disorder.
The acquisition will add a late-stage drug candidate with blockbuster potential to Lundbeck’s neuroscience pipeline.
The partners are preparing for commercialization of the lung cancer drug limertinib as they await an approval decision from China’s National Drug Administration.
SK Group’s contract development and manufacturing organization (CDMO) arm SK pharmteco is spending $260 million to expand its small molecule and peptide manufacturing muscle in South Korea.
One year after a rejection by the US Food and Drug Administration (FDA), the UK firm F2G has raised $100 million to push its candidate olorofim to the market for the treatment of rare fungal infections in 2026.
Creyon Bio Inc., a clinical-stage biotechnology company specializing in AI and machine learning-enabled oligonucleotide-based medicines (OBMs), recently announced the issuance of its second US patent.
Seqster and PatientsLikeMe have announced a strategic partnership to integrate real-time electronic health record (EHR) data with patient engagement tools, aiming to significantly improve clinical research and patient outcomes.
UCB, a global biopharmaceutical leader, has taken a significant step in refining its strategic focus by divesting its mature neurology and allergy portfolio in China.
SSNL - track and trace
In a strategic move aimed at transforming healthcare supply chains, TraceLink, a leading provider of digital supply chain solutions, has partnered with Tecsys, an industry leader in inventory and warehouse management systems.
In a significant move set to reshape the landscape of drug discovery, NovAliX, a leading Contract Research Organization (CRO) specializing in drug development, has entered a strategic partnership with Bruker, a global leader in scientific instruments.
As advanced therapies drive increasing market consolidation, the US giant Agilent Technologies has acquired the Canadian contract development and manufacturing organization (CDMO) BIOVECTRA for $925 million.
CatSci, a UK-based innovation partner for the development of pharmaceutical manufacturing processes, will be expanding its service offering with the acquisition of Reach Separations.
Under the terms of the agreement, Eli Lilly will obtain the exclusive rights to acquire Radionetics Oncology for $1 billion.
NeuroSense Therapeutics has announced positive phase 2b results for a drug combination designed to treat amyotrophic lateral sclerosis (ALS).
In a bold move set to reshape the global healthcare landscape, Asahi Kasei Corp. announced its intent to acquire Swedish drug maker Calliditas Therapeutics AB through a voluntary tender offer.
Swixx BioPharma AG, a platform dedicated to unlocking access to e medicines, has announced its strategic expansion into Latin America.
PrecisionLife, an innovative precision medicine company, and Metrodora Institute, a leading US multi-specialty healthcare center, have joined forces.
Walgreens and Boehringer Ingelheim have joined forces in a move to enhance diversity and accessibility in clinical trials, aiming to make participation more inclusive and equitable.
Adragos Pharma is a contract development and manufacturing organization (CDMO) that provides development and manufacturing services for drug products. It concentrates on small molecule dosage forms including sterile and non-sterile liquids, solids, and...
Precision oncology innovator SimBioSys and General Inception have joined forces in a strategic partnership aimed at revolutionizing cancer drug development.
Bora Pharmaceuticals Co., Ltd. yesterday (April 1) finalized the acquisition of Upsher-Smith Laboratories, Inc., a leading generics manufacturer based in Minnesota, U.S., from its previous owners, Sawai Group Holdings and Sumitomo Corporation of Americas.
Merck set to invest over €300 million in new production center in South Korea.
Roquette has acquired the pharma solutions division at International Flavors & Fragrances, in a deal up to $2.85 billion.
Lonza is set to acquire a large-scale manufacturing site from Roche-owned U.S. giant Genentech for $1.2 billion.
Yesterday (March 18) PureTech Health plc announced the completion of the acquisition of its founded entity, Karuna Therapeutics, Inc., by Bristol Myers Squibb for a staggering $14 billion.
Venture Capital firm, Negev Capital, holds a portfolio of companies creating neuropsychiatric drugs based on psychedelic molecules.
Connectivity for research site processes and research has strengthened significantly following a partnership between Florence Healthcare and Slope.
Today (February 12) Saama has announced a newly expanded, multi-year agreement with biopharma giant, Pfizer, to help expedite clinical research.
Announced today (January 25), Quibim, a company transforming imaging data into actionable predictions of cancer progression and treatment responses, has partnered with Merck KGaA.
Bora Pharmaceuticals is set to acquire US pharma manufacturer Upsher-Smith Laboratories for up to $210 million, it says, to fuel global expansion.
Inceptua Group and Cycle Pharmaceuticals partnership will give access to Free Goods Partnership that gets medicine to patients with extremely rare genetic conditions, which they would be unable to access otherwise.
With innovative and flexible lab and manufacturing solutions being a critical success factor in drug development and delivery, SmartLabs, was delighted to announce the raise of $48 million series C financing.
An alliance between KBI Biopharma Inc., and Argonaut Manufacturing Services Inc., has been formed so biopharma clients can receive end-to-end drug substance and drug product manufacturing solutions.
Clinical-stage drug delivery and development company DelSiTech has made the biggest single financing round in its history with the successful completion of a €10 million deal.
Pharma giant, GSK, plans to invest £200 million ($253 million) into the UK over the next two years and has acquired Aiolos Bio for $1.1 billion (£870 million).
SGD Pharma has announced its goal to become the global market leader in primary pharmaceutical glass packaging.
Evotec’s end-to-end integrated research and development platform will be able to advance drug discovery for two drug targets which is why it has joined forces with the Crohn’s & Colitis Foundation.
AION Labs, the first-of-its-kind venture studio today (January 8) announced its new partnership with Amiti Ventures, a leading early-stage venture capital firm in Israel.
Novartis is paying Isomorphic Labs $37.5 million upfront to collaborate on small molecule drug discovery.
Bristol Myers Squibb has announced it has acquired Karuna Therapeutics, Inc., for a total equity value of $14 billion or $12.7 billion net of estimated cash.
Decentralized clinical trials (DCTs) are gaining increasing interest as they have the potential to make clinical trial operations quicker, more efficient and more accessible to patients. Check out five DCT organizations that have raised big venture...